Posted on September 16th, 2014
by James Joyce
Over the weekend, the New York Times published a front-page article entitled; “Brain Trauma to Affect One in Three Players, NFL Agrees“, which discussed the high rate of chronic neurological disorders in former NFL Players. More specifically, the National Football League stated in federal court documents that it expects nearly a third of retired players to develop long term cognitive problems and that the conditions are likely to emerge at “notably younger ages” than in the general population. The article also referenced that Chronic Traumatic Encephalopathy (CTE), a degenerative brain disease found to be prevalent in former NFL players, could only be identified after death at autopsy.
Thanks to discoveries made by Dr. Douglas Taylor and our research team at Exosome Sciences (Aethlon Medical subsidiary), the possibility of a blood-based “liquid biopsy” to identify and monitor CTE in a living person now exists. To date, CTE has been identified at autopsy in thirty-three (33) of thirty-four (34) NFL players examined. The list includes Junior Seau (San Diego Chargers), Mike Webster (Pittsburg Steelers), Dave Duerson (Chicago Bears), Andre Waters (Philadelphia Eagles) and my high school and college teammate Tom McHale (Tampa Bay Buccaneers). The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brain cells in areas that control memory, emotions and other functions. Earlier this year, we disclosed that our Exosome Sciences (ESI) team had isolated exosome-based biomarkers transporting tau protein across the blood-brain barrier and into the circulatory system.
As a result of this discovery, we have initiated follow-on studies to advance a diagnostic candidate that offers to identify and monitor the progression of CTE. If successful, the stage would then be set for industry colleagues to begin development of candidate drugs to address CTE. If a therapeutic mechanism that reduces the presence of circulating exosomal tau is required, we would seek to clinically test the benefit of the Aethlon Hemopurifier® as the affinity techniques that allow for our ESI team to isolate exosomal tau also reside within our therapeutic device. In this scenario, the ESI diagnostic advancement could become a companion that identifies when to initiate Hemopurifier® therapy for this specific disease indication. We are now preparing to launch the first FDA approved studies of Hemopurifier® therapy in the United States and hope you choose to follow our clinical endeavors. Our mission is simply to save lives.
Forward Looking Statements
This blog contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary. will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2015, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.